News >

Imatinib Continues to Impress in Long-Term CML Analysis

Silas Inman @silasinman
Published: Friday, Mar 10, 2017

Dr. Brian Druker

Brian Druker, MD

Imatinib (Gleevec) continued to show dramatic overall survival (OS) benefits after nearly 11 years of follow-up and despite crossover for patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), according to long-term findings published in The New England Journal of Medicine.

Imatinib, which is broadly considered the first precision cancer medicine, was approved for the treatment of CML in 2001, based on phase II findings. The phase III IRIS study began enrolling patients in June 2000, with the last patient accrued in 2012. Since its approval, several other BCR-ABL TKIs have also gained approval for patients with CML, completely altering the natural history of the disease.
Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917-927.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication